Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 18,391 matching trials from the live ClinicalTrials.gov search.
Conditions
End-stage Renal Disease
Interventions
ammonium chloride or sodium citrate/citric acid, Sodium citrate/citratic acid
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Torrance, California
Conditions
Symptomatic Aortic Stenosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
1,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Prematurity
Interventions
Oral feeding
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 7 Weeks
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions
Pembrolizumab, Propranolol Hydrochloride, Nivolumab, Avelumab
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer AJCC v7
Interventions
Cryosurgery, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Tremelimumab
Procedure · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Bladder Cancer
Interventions
cisplatin, gemcitabine hydrochloride, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
210
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Conditions
Otitis Media, Urinary Tract Infection, Asthma, Head Injury
Interventions
patient-driven health IT product
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 12 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts • Weymouth, Massachusetts
Conditions
Acute Renal Failure
Interventions
Renal tubule assist device
Device
Lead sponsor
RenaMed Biologics
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Augusta, Georgia • Chicago, Illinois + 10 more
Conditions
Renal Cancer
Interventions
Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Biological · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Tumor Gene Expression in Women With Ovarian Cancer

NCT00817479
Conditions
Ovarian Cancer
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Smoking Cessation, Pregnancy, Communication Research
Interventions
Clinician Communication Intervention, 5A's lecture
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Metastatic Breast Cancer, Neoplasms, Breast
Interventions
Investigational Cancer Drug
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Chula Vista, California • Los Angeles, California • Poway, California + 24 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prevention of Alcohol-related Sexual Revictimization in College

NCT05257603
Conditions
Sexual Assault
Interventions
RPCW, HEC
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 22 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Preterm Birth, Child Development
Interventions
Docosahexaenoic Acid + Arachidonic Acid (DHA+AA), Placebo
Drug · Dietary Supplement
Lead sponsor
Sarah Keim
Other
Eligibility
10 Months to 16 Months
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Newton, Kansas • Syracuse, New York • Ellensburg, Washington
Conditions
Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma, Mesothelioma, Breast Carcinoma, Esophageal Carcinoma, Gastric Cancer, Pancreatic Carcinoma, Neuroendocrine Cancer, Liver Cancer, Gallbladder Cancer, Biliary Tract Cancer, Anal Carcinoma, Bone Sarcomas, Soft Tissue Sarcomas, Carcinoma of Unknown Origin, Primary
Interventions
PSMA/PRAME
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more
Active, not recruiting Not applicable Interventional

Myo-Inositol for Infertility in PCOS

NCT04407754
Conditions
Polycystic Ovary Syndrome
Interventions
Inositol supplement, Placebo supplement
Dietary Supplement
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 36 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Endometrial Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Metastatic Renal Cell Carcinoma
Interventions
placebo, Sorafenib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Coronary Artery Disease
Interventions
Adenosine SPECT myocardial perfusion imaging, Combined adenosine / exercise SPECT myocardial perfusion imaging
Procedure
Lead sponsor
Midwest Heart Foundation
Other
Eligibility
60 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
20
States / cities
Tucson, Arizona • Roseville, California • Sacramento, California + 16 more
Conditions
Uterine Prolapse
Interventions
Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP), Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
7
States / cities
Jacksonville, Florida • Chicago, Illinois • Durham, North Carolina + 2 more
Conditions
Chronic Kidney Diseases, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage V, Chronic Kidney Disease Stage 5, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage I, Chronic Kidney Disease, Stage IV (Severe), Pediatric Kidney Disease
Interventions
My Kidney Guru
Other
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
13 Years to 25 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Conditions
Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
Interventions
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Conditions
IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Interventions
atrasentan
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois